Recent Posts
Social•Feb 20, 2026
Madrigal Slides as Ex-Novartis Exec Joins Daiichi
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi https://t.co/ymSJ5qY8kq $MDGL $NVS $JNJ $ACIU #biotech
By Ben Fidler
Social•Feb 19, 2026
Altesa Secures $75M for Lung Drug, Led by Ex‑Trump Official
Altesa, run by former Trump official, raises $75M for well-traveled lung drug https://t.co/bUx5dcvNJy by @gwendolynawu #biotech #startups
By Ben Fidler
Social•Feb 19, 2026
FDA Proposes Single Pivotal Trial as Approval Standard
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals https://t.co/ADRb1miphf by Kristin Jensen #biotech
By Ben Fidler
Social•Feb 12, 2026
Biotech Earnings: Neurocrine Drops, Alnylam Faces Skepticism
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor https://t.co/kU1ex80A24 by @realJacobBell $NBIX - 10% $ALNY - 4% $ASND - 2% $BBIO #biotech
By Ben Fidler
Social•Feb 12, 2026
Seres Cuts Staff and Pauses Flagship Program
Seres to lay off staff, pause top program in latest reboot https://t.co/yJRtypSN3d by @Lilah_Alvarado $MCRB - 37%
By Ben Fidler
Social•Feb 12, 2026
Sanofi Appoints Ex-Merck KGaA Chief Garijo as CEO
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo https://t.co/SDLUYOzPuD by Kristin Jensen $SNY - 4% $MKKGY
By Ben Fidler